堀口 智也

BACKGROUND: Although bronchoscopic biopsy serves as a cornerstone for diagnosing lung cancer in elderly patients, whether this procedure leads to clinically relevant outcomes is still unclear. This study aimed to clarify the clinical significance of diagnostic bronchoscopy in lung cancer patients aged ≥80 years. METHODS: We retrospectively analyzed 803 patients diagnosed with lung cancer who underwent bronchoscopy at our hospital from April 2015 to March 2019. Those aged ≥80 years and <80 years were classified as the elderly group (n = 154) and young group (n = 649), respectively. RESULTS: The diagnostic yield of bronchoscopy in the elderly and young groups was 92.9 % and 83.5 %, respectively; complication rates were 9.6 % and 7.2 %. Approximately 89 % of the patients in the elderly group received specific lung cancer treatment. The 5-year survival rates for elderly and young patients who underwent surgery were 74.5 % and 78.2 %, respectively. In the elderly group, 11 % of the patients chose best supportive care (BSC) only, compared with 2 % in the young group. Notably, patients with non-diagnostic bronchoscopic results selected BSC more frequently in the elderly versus young groups (30.4 % versus 0 %, respectively). CONCLUSIONS: Bronchoscopy in elderly patients with lung cancer demonstrated a high diagnostic yield and an acceptable safety profile, enabling specific treatments in the majority of cases. These findings support the clinical usefulness of bronchoscopy in guiding treatment decisions for elderly patients. However, non-diagnostic results were associated with a higher likelihood of BCS, highlighting the importance of achieving a definitive diagnosis in this population.

Bronchoscopic lung volume reduction (BLVR) with endobronchial valves is an established treatment for selected patients with advanced emphysema. A 74-year-old male patient with chronic obstructive pulmonary disease and severe dyspnea was scheduled to undergo BLVR targeting the right middle lobe bronchus based on high-resolution CT findings, which showed severe emphysematous changes with hyperinflation and fissure completeness of 98% in the right middle lobe. The physician conducted preoperative virtual reality (VR)-assisted planning using the patient's imaging data, enabling comprehensive visualisation of the bronchial tree, airway measurements, and procedural simulation. The Chartis system confirmed a 'no flow' pattern, supporting the absence of collateral ventilation. During the procedure, a size 5.5 valve was placed in the right B4/5 bronchus following VR and intraoperative assessments. The patient remained stable postoperatively without complications. VR enhanced procedural planning by improving airway assessment, optimising valve sizing, and reducing cognitive load, leading to increased efficiency and operator confidence. Further research is warranted to validate the utility of VR in bronchoscopic interventions.

Epithelioid hemangioendothelioma (EHE) with pleural involvement presents significant diagnostic challenges, particularly in terms of differentiating it from malignant pleural effusion caused by other types of cancer, such as lung carcinoma. While most cases of EHE follow an indolent course, some can deteriorate rapidly, particularly those with serosal involvement such as pleural metastasis. In this report, we describe a case in which semi-rigid thoracoscopic cryobiopsy under local anesthesia yielded adequate specimens safely for diagnosis of pleural dissemination of EHE. The patient was a 46-year-old woman who had been diagnosed with multifocal EHE affecting the liver and both lungs a decade earlier. After radiofrequency ablation for the hepatic lesions and 2 years of chemotherapy, she was monitored without specific treatment for approximately 8 years with no significant tumor progression. She presented to our department following a rapid increase in left-sided pleural effusion over the previous month. Based on the clinical course and imaging findings, the diagnosis was initially difficult. However, thoracoscopic cryobiopsy provided definitive confirmation of pleural EHE.

The purpose of this study was to evaluate how the first oral administration of suvorexant affects PSG results in patients with severe obstructive sleep apnea (OSA). Single-center, prospective study conducted in a nonrandomized, uncontrolled, unblinded fashion. Undiagnosed 64 patients with suspected OSA underwent first-night PSG, and 30 patients with severe OSA (Apnea Hypopnea Index [AHI] ≥ 30 events/h) underwent second-night PSG testing after administration of 15 mg suvorexant. The change in AHI between the first and second nights was not significant, although the upper limit of the 95% confidence interval for the mean difference in AHI was high at 5.987.The mean duration of apnea on the second night was significantly prolonged compared to that on the first night, but there were no significant differences n 3% oxygen desaturation index, saturation of percutaneous oxygen<90% time. On the second night, total sleep time was significantly prolonged, mid-night awakenings decreased, REM sleep percentage increased, and REM latency was shorter. Because the environment for PSG testing is very different from the patient's home and many patients have difficulty sleeping, there are clinical cases in which PSG is performed with sleep medication. In this study, PSG after oral administration of 15 mg of suvorexant on the second night showed no significant difference or clear trend in AHI. However, the upper limit of the 95% confidence interval for the mean difference in AHI was greater than 5, suggesting that suvorexant may exacerbate AHI, even with the first administration.